Celltrion's Remsima Achieves Overwhelming Market Shares in Asia: 93% in Singapore, 77% in Hong Kong

Strengthening Biosimilar Leadership Through New Product Launches

Celltrion is strengthening its market presence in Asia by expanding prescriptions of its key biosimilar products through a direct sales system. Celltrion is leading the market in major Asian countries such as Singapore, Thailand, Malaysia, and Hong Kong, achieving overwhelming market shares.

According to pharmaceutical market research firm IQVIA on March 9, Celltrion’s flagship autoimmune disease treatment 'Remsima' (ingredient: infliximab) maintained the top prescription position in the third quarter of last year, recording market shares of 93% in Singapore, 77% in Hong Kong, 73% in Thailand, and 65% in Malaysia.

Celltrion’s local subsidiaries have built trust by increasing their success rate in tenders in the Asia market, leveraging supply stability, and consistently delivering contract volumes on time after winning tenders. Additionally, by actively participating in local academic societies to raise product awareness among healthcare professionals and by strengthening networks with major Key Opinion Leaders (KOLs), Celltrion has been expanding its prescription base.

Celltrion autoimmune disease treatment Remsima. Celltrion

Another autoimmune disease treatment, 'Yuflyma' (ingredient: adalimumab), is also expanding its growth momentum in the Asian market, building on the success of Remsima. In Singapore, Yuflyma has surpassed the original product to secure the second largest market share, and its prescription growth continues.

Celltrion Singapore has launched a 20mg dosage of Yuflyma in addition to the existing 40mg, aiming to gain a competitive edge and accelerate market share expansion in this year’s adalimumab tenders. Furthermore, Celltrion has newly launched Yuflyma in Malaysia and Thailand and plans to further expand prescriptions through sales and marketing strategies tailored to the competitive landscape and market characteristics of each country.

In addition to autoimmune disease treatments, Celltrion’s oncology products are also achieving strong results in major Asian markets. The breast and gastric cancer treatment 'Herzuma' (ingredient: trastuzumab) showed clear prescription superiority in the third quarter of last year, with market shares of 87% in Thailand, 57% in Hong Kong, and 51% in Malaysia. The blood cancer treatment 'Truxima' (ingredient: rituximab) also maintained the top prescription position with a 90% market share in Singapore and 79% in Thailand.

Notably, Celltrion Thailand has established long-term cooperative relationships with all university hospitals in the country, earning recognition for the quality competitiveness of its key products, including Remsima, Truxima, and Herzuma. As a result, these three products are exclusively used in all university hospitals, delivering differentiated prescription outcomes. In Thailand, despite intensified sales competition since 2023, when approvals became possible based solely on domestic clinical trials, Celltrion has succeeded in strengthening its market influence through trust based on product quality and the business and marketing capabilities of its local subsidiary.

Building on the success of its existing product lineup, Celltrion continues to expand its product portfolio in the Asian market by launching new products. In Singapore, eight autoimmune disease and oncology treatments are currently being sold, and the company plans to further strengthen its portfolio by obtaining approval for 'Stovoklo-Osenbelt' (ingredient: denosumab) within this year. Celltrion Thailand also plans to enhance sales synergy by launching three new products this year—'Stekima' (ingredient: ustekinumab), 'Begzelma' (ingredient: bevacizumab), and 'Omriclo' (ingredient: omalizumab)—in addition to its current five products.

A Celltrion official stated, "We are improving prescription outcomes in the tender-driven Asian market based on product competitiveness and supply stability, and as a result, positive perceptions of Celltrion products are spreading rapidly. We will make every effort to further boost the performance of existing products and ensure the smooth launch of new products in order to achieve early market entry and improve profitability at the same time."

This content was produced with the assistance of AI translation services.